Mei Ri Jing Ji Xin Wen·2026-02-26 23:08Group 1 - Three companies, Jinxin Kangyang, Tianchen Biopharmaceuticals, and Hanfang Pharmaceutical, have submitted listing applications to the Hong Kong Stock Exchange, indicating strong interest in the healthcare sector [1] - Jinxin Kangyang focuses on providing integrated medical and elderly care services to the aging population in China [1] - Tianchen Biopharmaceuticals specializes in the discovery and development of biopharmaceuticals for allergic and autoimmune diseases [1] - Hanfang Pharmaceutical is engaged in the production, sales, and research of traditional Chinese medicine, particularly in treating skin and mucosal diseases [1] Group 2 - Hong Kong Exchanges and Clearing Limited reported a record revenue and other income of HKD 29.161 billion for 2025, a 30% year-on-year increase [2] - The increase in trading and settlement fees was driven by record trading volumes in the spot, derivatives, and commodities markets, with main business revenue rising by 32% [2] - Shareholder profit attributable reached HKD 17.754 billion, up 36% year-on-year, reflecting a robust trading environment [2] Group 3 - Trip.com Group reported a significant increase in net profit attributable to shareholders, rising by 95.08% year-on-year to HKD 33.294 billion for 2025 [3] - The group's net operating revenue was HKD 62.4 billion, a 17% increase compared to the previous year [3] - Basic earnings per share were HKD 0.5062, indicating strong financial performance despite management changes [3] Group 4 - Galaxy Entertainment reported a 13% year-on-year increase in net revenue, reaching HKD 49.2 billion for the year ending December 31, 2025 [4] - Adjusted EBITDA rose by 19% to HKD 14.5 billion, while profit attributable to shareholders increased by 22% to HKD 10.7 billion [4] - Basic earnings per share were HKD 2.44, benefiting from the recovery of the Macau tourism and gaming market [4]